J. Wolchko
a afternoon, of the Good Call. everyone, joining on we for after which these Thank be website can Therapeutics and under First for found issued today, Time Fate p.m. Investors Results release Quarter us with X:XX results, section you. the Eastern thanks, press our XXXX Shortly Releases. Financial Press
section filed the of shortly Information. Form our March ended addition, on Financial quarter the website XX-Q found our for Investors and under thereafter XXXX, In can be was XX,
differ Private Before cause we this that XXXX. of management historical actual statements begin, forward-looking provisions can I results for of the that disclaimer included the those to ended involve Securities Please statements statement on uncertainties remind forward-looking such These forward-looking the our risk that issued to the by the call conference would the XXXX. XX, filed release March SEC facts, Litigation company's quarter and except everyone was materially see XX-Q with like well under Reform and made Form as from questions press in harbor today as after statements of the statements. on Act for to risks are responses the factors in statements The safe earnings the today. market of close
or reflect circumstances disclaims events only Undue future placed to any and forward-looking forward-looking the these update of as circumstances. these speak law, they may reliance Fate date required be forward-looking made, change. which obligation by Therapeutics not facts underlying should statements, Except information, statements are as on statements to as
Officer; and Dulac, Bob Ed Development and Dr. Research our me Joining Valamehr, today's on are our Officer. Chief Chief call Financial
differentiation at Meeting are programs initiatives our CAR on outcomes. the therapeutic cell focus the and NK FTXXX to Annual Gene FTXXX and of today's today pursuing will and program that discuss off-the-shelf for we CAR improved We and Cell patient Therapy American T-cell presented achieve data Society remarks key
we our will clinical that highlight autoimmune treatment we and to readouts product across are for iPSC and addition, the projecting XXXX cancer In pipeline diseases. achieve in of
our the first quarter cash into of where Finally, capital second XXXX. we runway balance position raise strong half created have operating will review and our financial
off-the-shelf rapid, included and these tissue depletion B-cell studies activated plasma mechanisms B-cell CAR-T Phase cell cell-mediated B reset mechanisms program. that presented elimination of in deep autoimmune malignancies, with an secondary diseases. Beginning tertiary immune or of primary, translational The show our CDXX-positive Annual memory infiltration supporting dose B-cell blood, with the from study FTXXX B-cell with and of Meeting, CDXX in recovery data of depletion cell plasma which implicated and sustained reconstitution ASGCT FTXXX, in of with blasts. patient at case action generating studies little targeted data naive in activity refractory relapsed of B-cell Today, and a CDXX-positive recovery tissue exhibited and translational patients our I and multiple peripheral FTXXX no single the case in patient we trafficking, B-cells to
FTXXX presented agent. the studies these believe we clinical deep the B-cell-mediated Collectively, rapid, fludarabine also depletion. case support patient of by potential sustained conditioning patients diseases. we a B-cell Notably, use demonstrating disease-modifying data as without autoimmune with of Accompanied and responses for
adverse a without care chemotherapy The therapies, received has woman events. of patient a any previously of stay XX-year-old a X-day to This was first autoimmunity Phase dose am FTXXX treated I pleased conditioning FTXXX. end, announce multiple refractory the followed disease I been with our treated that of study in notable that despite by patient single cells. at To first after XXX lupus standard with having patient been million discharged hospitalization
Using a we the CDXX with observed depletion assay. also we the B-cells presented to patient's of today, chemotherapy, obtained positive prior blood At potent ASGCT sample an data assay of and administration in where FTXXX. cytotoxicity first-of-kind of translational rapid vivo promising patient's a conditioning from ex
treatment of patient note complex experience patient site logistics, with extended therapy to autologous including occurred this worthwhile believe and of patient reaching apheresis, off-the-shelf potential in treatment this manufacturing weeks need to challenges We within that that activation. first exemplifies and an diseases, therapies of the overcome cell hospitalization. autoimmune may is for hinder It cell the patients
clinical disease-modifying and fludarabinefluderapy using have Phase Furthermore, since conditioning our a we believe as autoimmunity of agent FTXXX alternative malignancies. study B-cell observed regimens. We use I deep of in potential have conditioning responses, for in the B-cell may depletion without FTXXX
to We Phase add-on administration the with We experience. plan rheumatologists differentiating treatment at FTXXX patient XXXX may our a in single to of enable patients study autoimmunity regimens contribute second same amend the with off-the-shelf of for cytoxan by I for highly used disease. to dose an believe treatment current the agent used to of clinical autoimmune commonly that quarter protocol FTXXX
our malignancies I in autologous in clinical matching. therapy. aggressive complete relapsed/refractory has patients targeted FTXXX responses escalation including billion FTXXX up heavily single with in disease, pretreated including lymphoma CAR-T now large Phase that in at cell X were to without previously treated dose cells refractory B-cell with were responses, patients We patients XX CDXX B-cell with relapsed observed Where of Dose completed. a study treated HLA
dose-limiting patients and no CRS. diseases. all low and low-grade in exclusively focus and is of And time, to no development the treatment this was autoimmune incidence significant tolerability of intend of favorable of we safety clinical toxicities, established of FTXXX be FTXXX further of host profile with may autoimmunity. differentiated. of tolerability FTXXX safety At The disease of We believe graft or also only ICANs for any profile import clinical with versus events grade
CDXX receptor product which also from technology. ASGCT the first cell targeted defense immune at the presented our iPSC off-the-shelf that data emerging CAR Today, platform Annual [ NK incorporates Allen FTXXX ] program, product Meeting, is candidate we our from
therapies chemotherapy. XXX and Conditioning chemotherapy toxicities, allogeneic care technology of ADR with potential in used therapy patients ]. standard induce requires can combination for including cell-based is with to chemotherapy Today, the of immunotherapies treatment patients. course prevent access the autologous settings, without into paradigm widely conditioning the community-based administration both effective incorporated treatments treatment and reach. of patient treatment to enable the [ has to redefine limit and believe Which cell conditioning we administration designed cell
the previously presented potential has alloreactive to NK increases reactive proliferation have that persistence lines We that ] antitumor cell coculture enable cell demonstrating Apollo with cell NK NK in of cells effector [ an cell indicating ADR using armed system. cells enhances and the ADR preclinical data CAR promotes cancer technology activity, of T with arming presence the function
an functional ASGCT alloreactive B-cells cells In the SLE uniquely using a Annual at rechallenge. rechallenging SLE donor peripheral mononuclear and preclinical positive we assay kill Today, data rapid drove additional reported cells deep maintained FTXXX B-cells Meeting of from the T disease blood novel to depletion ability eliminated and persistence CDXX donor upon donor. unmatched cells. donor with positive using CDXX
NK show our in to initial ADR In in technology. from clinical relapsed without data of the study with data translational we FTXXX, These prior our in the B-cell treated also ongoing data addition, patients X refractory CAR periphery cell first persistence lymphoma. presented I compared CDXX XXX of targeted enhanced observed generation Phase FTXXX
the also conditioning IND middle FDA to cycle. for application expand of submit Importantly, various patients. and show investigation X-month clinical including the treatment We of treatment FTXXX deep of in chemotherapy administration an depletion periphery to sustained autoimmune to mediated these data the to throughout diseases, rapid, intend the our B-cell of XXXX in B-cell without
FTXXXX that first report Dose any events dose-limiting to any study B-cell grade per of the CRS, the pleased or our lymphoma also dose. is I'm of patients refractory were of X of conditioning toxicities. there ICANS completed have assessment a now for cells million relapsed arm at Phase now XXX And safety ongoing GVHD. escalation I in no without
initiated been In cell ADR to NK cells XXX to conditioning addition, patient without arm we our clinically safety dose. patients. conditioning of of the at no per FTXXX and million enrollment activity chemotherapy in program armed poised the CAR has administration are And assess now
pleased announce also under our Turning initiatives. our that to collaboration to Ono with tumor solid Pharmaceutical. I'm
constellation using an frontier FDA have we immunotherapy. recently in first treated FTXXX, I new our both of platform, tumors. innate the of in company's the IPS-derived engineered program cancer antitumor field synthetic represents product overcome cell and believe study treating and to designed the of cell-based potential multiplexed A a We mechanisms XX exciting solid unique patient incorporates of Phase adaptive to in that iPSC CAR-T the immunity are harness designed challenges
differentiated HERX HERX-targeted CXCRX activity a cellular -- Including promote to tumor trafficking, cancer CDXXA specific trastuzumab chimeric to redirect cytotoxicity low domain, include receptor a ] if high-affinity studies. expressing These tumor microenvironment. cells. binding has signals in TGF-beta antibody-dependent in novel receptor preclinical which shown to [ the non-cleavable against cell immunosuppressive antigen promote from a a that and mechanisms receptor
diagnosed had administered conditioning gastroesophageal HERX-positive The of first monotherapy And cells. FTXXX patient junction including multiple chemotherapy receiving in was the XXX Phase as study at was with by progressed million therapies. followed adenocarcinoma of single standard dose HERX-targeted lines treatment, a after I
convenience our strategic and autoimmunity differentiating cell patient scale believe as product therapies may platform as and off-the-shelf we there As proposition in and key a safety value strong direction, we consider for for factors. cost iPSC is our accessibility be well
and to to ADR treatment redefine therapy conditioning the cell without has requiring believe treatment with patients, cancer paradigm administration effective cell autoimmunity. patient experience technology and for chemotherapy We can enable potential of therapy the our which
believe And to solid of challenges tumors. with multiplex we engineered multiple can our in the synthetic deliver mechanisms antitumor overcome cell unique CAR activity T platform potential treating iPSC-derived
positioned demonstrate autoimmune a iPSC transforming report for B-cell-mediated the into diseases. cancer to autoimmune well key pipeline ahead Number of the we look one, diseases. across we half As reach milestones of we and on disease to seek product potential XXXX, are X second in our FTXXX clinical
treated for to expect data Phase we out I FTXXX to first initial clinical X SLE. patients for with severe Specifically, X read to the moderate
seek instead used fludarabine diseases. Number we commonly with to autoimmune treatment without for administer and regimens FTXXX two,
administration intend we initial amend cytoxan, to our to expect Phase data. Specifically, single-agent out FTXXX the study autoimmunity read IND include with clinical and to for I patient current
potential seek ADR of to proprietary our effective without patients of Number three, of technology enable administration we treatment chemotherapy. to demonstrate conditioning the
study we lymphoma. treated our Phase read the X out patients first expect to Specifically, for no XXX with I B-cell conditioning in
broadly we autoimmune Number conditioning XXX treatment chemotherapy to investigate without B-cell of various mediated for diseases. seek four,
to subject patient an initiate to IND and in multi-indication study application allowance we autoimmunity. Specifically, submit FDA, I XXX for enrollment expect the a of by Phase IND
we our in ] an engineered multiplexed iPSC-derived proof tumors. for clinical initial of seek [ platform And concept establish CAR cell solid T finally, to treating
Specifically, first treated X X solid advanced Phase with patients FTXXX for we to tumors. to in study out our expect I read the
call first quarter. to the financial for like over now turn I Ed would results to the our review to
